|
|
| Countries covered: United States Research Overview
Market Sectors
The following technologies are covered in this research:
Underserved Multiple Sclerosis Therapy Market Gets a Lifeline with the Development of Numerous Treatment Options Healthcare companies across all tiers of competition are beginning to sit up and take notice of the U.S. multiple sclerosis (MS) market, following a spate of innovations in therapies. Big pharma, specialty pharma, niche pharma, biotechnology, and start-up companies could soon fill the vacuum created by the lack of an outstanding treatment option. "The pipeline for MS is robust, with a strong mix of early stage and late stage products, offering improved methods of treating and possibly, curing the disease," says the analyst of this research service. The market is expected to experience a boom between 2007 and 2013 with the launch of oral therapies as well as improved versions of interferons. Innovations will stand market participants in good stead, since healthcare providers are hoping to improve the standard of care and patient compliance. Multiple sclerosis treatment could go through a paradigm change due to the introduction of these therapies, since patients who failed interferon therapy or quit treatment due to side effects will still have an array of options, unlike earlier. Wide-ranging Therapies in the Pipeline Address Various Types of Multiple Sclerosis "The pipeline for MS treatments includes a variety of innovative treatment options ranging from oral therapies to vaccine-based treatments," notes the analyst. "While traditional injection-based interferon therapies continue to remain the cornerstone of treatment, the next generation of therapies in development is dominated by oral formulations that cater predominantly to the relapsing remitting type of MS." The unmet medical needs in primary progressive MS (PPMS) and secondary progressive MS (SPMS) segments are opening up significant market expansion opportunities for participants. Vendors are testing existing products for label expansion into other market segments, while simultaneously working on launching innovative therapies for the same purpose. |
More United States CNS/Neurology Reports
Mental Retardation Facilities in the US - Industry Risk Rating Report by
IBISWorld
This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Mental Retardation Facilities in the US industry. Industry Risk is assumed ...
Product Profiles: Autism Spectrum Disorders -Underserved market eagerly anticipates pipeline trial data by
Datamonitor
Introduction Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006, Risperdal became the first drug to ...
Case Study: Autism Spectrum Disorders - Public awareness and physician detailing will drive market growth by
Datamonitor
Introduction To date, only two products have gained approval for the treatment of ASDs; Risperdal (risperidone; Johnson & Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals) are ...
2008 U.S. Drug Delivery: Neurological Disorders - Physician Perspective by
Frost & Sullivan
This research service encompasses feedback on aspects of drug delivery and drug treatment provided by physicians in the U.S. who treat neurological disorders in order ...
Neurostimulation by
Global Industry Analysts
This report analyzes the Global markets for Neurostimulation in US$ Million Tby the following Product Segments: Spinal Cord Stimulators (SCS) {Radio Frequency (RF) System, Implantable ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>
Related Markets
- Diseases & Conditions
- Autoimmune
- Multiple Sclerosis (MS)
- Pharmaceuticals
- Drug Discovery
- Therapeutic Area
- CNS/Neurology
CNS/Neurology Reports
- Traumatic Brain Injury Global Clinical Trials Review, H1, 2012
- Tension -Type Headache Global Clinical Trials Review, H1, 2012
- Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012
- Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012
- Brain Ischemia Global Clinical Trials Review, H1, 2012
